Blog

Shares in this Australian stem cell company are going nuts on an investment … – Business Insider Australia


Brisbane Times

Shares in this Australian stem cell company are going nuts on an investment
Business Insider Australia
The US company will also get a six-month right of first refusal on Mesoblast's proprietary adult stem cell product candidates for the prevention and treatment of acute graft versus host disease, certain cancers, inflammatory bowel diseases and organ
Mesoblast Shares Climb as Celgene Invests $45 MillionBloomberg


Mesoblast takes partnership with Celgene, shares rise 27pcSydney Morning Herald
Celgene And Mesoblast Enter Into Equity Placement and Right of First Refusal GlobeNewswire (press release)
Nasdaq
all 22 news articles »

2015-04-13 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.